Cognitive impairmen...
Clear all

Cognitive impairment AA3 survivor

2 Posts
2 Users
0 Reactions
Joined: 3 years ago
Posts: 3
Topic starter  

My wife is an Anaplastic Astrocytoma survivor since 2019. She underwent only the brain surgery and she has followed  concomitantly radiotherapy and chemotherapy for 40 days. She hasn`t be able to take the planned chemotherapy with Temozolomide due to bad low platelets.   Since 2001 she is using different herbal remedies and supplements: for the first 1 year she got the Troglic herbal teas, then some propolis and bee products for the next 1 year.  For the last 6 months she is using  Salvestrols 12000 points per day, Magnesium L threonate, Vitamin D3 6000 ui, Liposomal Vitamin C  1000 mg, Curcumin 2000 mg and Berberine 500 mg.  Since  last spring, after a Covid episode and  being non vaccinated,  she has confronted  with cognitive impairment. Nevertheless last  three annual MRIs shows no regrowth but scare tissue from radiotherapy. What do you suggest for the management of the these these cognitive deficiencies(balance issues, short memory problems and fear of falling down). We would consider Lion's mane but  we have found out a study which tell us this: "Hericium erinaceus induced NGF synthesis and promoted neurite outgrowth in NG108-15 neuroblastoma-glioma cells". We are afraid to start the Lion's mane administration to avoid any cancer cells fuel supply. Please enlighten us.

Joined: 6 years ago
Posts: 2166

@gazamare Ginkgo Biloba could help:

Attia et al.35 evaluated the effect of 120 mg ginkgo biloba administered daily for 24 weeks, followed by a washout period of 6 weeks, on cognitive function, QOL and mood in irradiated brain tumour patients recruited from a US centre. There was no randomisation of participants, but participants served as their own control in this open-label study. The specific brain tumour subtypes and number of patients that received chemotherapy were not specified, but all participants had received partial or whole-brain radiotherapy at least 6 months prior to enrolment, had no imaging evidence of tumour progression in the preceding 3 months, were on stable or reducing doses of steroid therapy, and had no brain tumour treatment planned during the course of the study. Rates of steroid and anti-epileptic drug use were not reported. Of the 34 participants enrolled, 19 (55.9%) completed 24 weeks of treatment. Cognition was evaluated using a battery of tests covering global cognitive functioning, attention and concentration, visuoconstructional skills, verbal fluency, executive function, verbal learning and memory, and figural memory. Following 24 weeks of treatment, time taken to complete the Trial Making Test A (TMT-A) had significantly decreased (p = 0.002). Trail Making Test B (TMT-B) performance also improved significantly from 24 to 30 weeks, but TMT-A performance did not. Immediate and delayed recall scores on the Modified Rey-Osterrieth Figure also significantly improved (p < 0.001 and p = 0.002, respectively). There were no significant changes identified in measures of global cognitive function (MMSE), verbal fluency (F-A-S Test), or attention/concentration and working memory (Digit Span Test Total).